Last reviewed · How we verify
AD-218A
AD-218A is a small molecule that targets the SGLT2 receptor.
AD-218A is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | AD-218A |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, AD-218A reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. AD-218A's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-218A CI brief — competitive landscape report
- AD-218A updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI